21st Annual Scientific Meeting Posters

Click to view poster or abstract. Posters are listed in alphabetical order by first author.

Measurement of schizophrenia symptoms through speech phenotyping from PANSS recordings: a cross-study validation (Abstract)

Abbas

Translating animal models into clinical programs: The IRIS trial for investigational ML-004 in autism spectrum disorder (Abstract)

Abbs

Standardization of EEG enrichment marker acquisitions in a randomized, double-blind, placebo-controlled study of ALTO-300 in adults with major depression disorder (Abstract)

Anup

Analyzing referral influx patterns over a 24-hour period and the impact of timely responses on referral engagement in depression trials (Abstract)

Apter

Utility of negative symptom burden in predicting transition to psychosis among individuals at clinical high risk (Abstract)

Arnovitz

Preliminary development of the Assessment of Rapid Affect Change (ARAC): A novel measure for psychoplastogen response (Abstract)

Averill

Ultra-low dose buprenorphine to sustain antidepressant and antisuicidal effects of intravenous ketamine in treatment-resistant depression with suicidal ideation: Protocol design and preliminary results from a randomized controlled trial (Abstract)

Bandeira

Validation of a precision measure of cognitive change in a phase II clinical trial in early AD: The Early and Mild Alzheimer’s Cognitive Composite (EMACC) (Abstract)

Barnum

MedDRA coding conventions for describing unique psychoactive effects of empathogenic drugs (Abstract)

Beaster

Enrichment based on speech latency enhances treatment effects in a Phase III study of brilaroxazine (Abstract)

Cohen

The patient and clinician reported circumplex model of depression (Abstract)

Cole

Comparison of the ten-item pediatric Positive and Negative Syndrome Scale (PANSS-10) to the PANSS-6 in an adult, acutely exacerbated clinical trial population with schizophrenia (Abstract)

Daniel

The effect of healthcare practitioner-participant interactions on participant heart rate during esketamine treatment (Abstract)

Deschamps

Speech-based quality analysis in COA administration: Profiling clinician behaviors in MADRS interviews (Abstract)

Efstathiadis

A novel asynchronous video technology and service to secure protocol compliance in a phase 2 major depressive disorder trial (Abstract)

Elmi

Novel machine learning approach outperforms traditional approaches in major depressive disorder clinical trials: Identifying subpopulations based on treatment response (Abstract)

Geraci

Predictive biomarker discovery in schizophrenia using advanced machine learning to decode heterogeneity: Analysis of the CATIE schizophrenia trial (Abstract)

Geraci

Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials (Abstract)

Gold

Insights to action: A tech-enabled operational monitoring and reporting framework to achieve high adherence in clinical trials (Abstract)

Gross

Online advertising resulted in more educated participants and non-inferior screen fail rates when compared to offline methods in an Alzheimer’s disease clinical trial (Abstract)

Huoh

Predicting disease progression trajectories in individuals with amyotrophic lateral sclerosis using multimodal digital biomarkers (Abstract)

Kothare

The impact of PANSS change in screening on week 1 PANSS change in acute schizophrenia clinical trials (Abstract)

Kott

Speech measures associated with the course of symptoms severity in patients with MDD (Abstract)

Menne

Examining patterns of commonly observed quality issues across global schizophrenia clinical trial research sites (Abstract)

Micaletto

Qualification plan for the PSYCHS as a COA for attenuated positive symptoms in patients at clinical high risk for psychosis (Abstract)

Mourgues Codern

Using exploratory graph analysis (EGA) to determine the role of insight on SIGH-D administration in an open-label trial (Abstract)

Namaky

Psilocybin-occasioned mystical-type experience predicts less heavy drinking in patients with alcohol use disorder (Abstract)

Petridis

Implementing biomarker frameworks of Alzheimer’s and vascular disease trials to reduce cognitive decline in type 2 diabetes mellitus (Abstract)

Ruthirakuhan

Cannabis use in pregnant females: Importance for a need of biomarker for perinatal cannabis use (Abstract)

Satodiya

Development of the subject-rated Comprehensive Drug Withdrawal Scale (CDWS) to evaluate the physical dependence potential of investigational drugs (Abstract)

Setnik

Precision functional mapping trials – A biomarker platform for neuropsychiatric drug development (Abstract)

Siegel

Forecasting of change in speech function using remote assessment of acoustics (Abstract)

Simmatis

Remote assessment of cognition with the unsupervised version of the Cogstate Brief Battery: Association of composite endpoints with Alzheimer’s disease biomarkers (Abstract)

Sink

Connectome predictive modelling of PTSD symptom severity (Abstract)

Tamman

Practice effects in digital semantic verbal fluency assessments improve detection of cognitive impairments in an older-age memory clinic population (Abstract)

Tröger

Acceptability and validity of the smartphone-administered version of the Cogstate Brief Battery in middle-aged and older adults of the Healthy Brain Project (Abstract)

Wacker

Development of a Bayesian progression model to assess the impact of an intervention on the progression of multiple system atrophy (Abstract)

Wiedemann

Evaluating the relationship among esketamine monotherapy efficacy and dissociation in patients with treatment-resistant depression (Abstract)

Williams

Generative AI-enhanced language analysis for early detection of psychosis risk (Abstract)

Wolff

Device agnostic digital Digit Symbol Substitution Test (DSST) for use on smartphones and tablets (Abstract)

Xu

Optimize clinical trial design to study nutraceutical correction of essential fatty acid ratio for weight restoration and maintenance in anorexia nervosa (Abstract)

Yang

Optimizing composite endpoints: A machine learning approach to improve signal detection in clinical trials for neurodegenerative diseases (Abstract)

Zhuang